One hopes it doesn't take data from a failed clinical trail (covid) to make the IPF/CC clinical trial worth the effort. The IPF/CC trial is what it is as of right now. Other data cannot change the primary endpoint. Bellus Health failed their primary endpoint and revamped ot to include multiple arms and doses (6 arms). The fear here is the trial design being fundamentally flawed with its tiny participant group, no placebo, and only one treatment dose of 20 mgs. That doesn't leave much room for error. Time will tell and time is the enemy.
Just noting - Yost went to Owlstone Medical (former Breathtec Biomedical's primary competitor). A traitorous move in the dark of night and management never told us. Also, there is no CSO at Algernon to replace Dr. Williams and I suspect there never will be being that the Repurposed Drugs strategy was his own. AP will simply feed off of what the have going now with Ifenprodil and the new fouud DMT angle. That, coupled to cancer will give them at least a 10 year runway to run tiny trials.
News 
Market Data 
Discover 
